Saroglitazar ameliorates alcoholic liver disease and is associated with enhanced ethanol metabolism

Figure 1 Effect of saroglitazar on plasma alanine aminotransferase, ethanol, and acetate levels in the preventive study design. Mice were administered saroglitazar or vehicle during a 10-day ethanol-feeding protocol. Blood samples were collected 2 hours after the ethanol binge to measure plasma ethanol and acetate levels, and 9 hours after the binge to assess plasma alanine aminotransferase. A: It shows plasma alanine aminotransferase concentrations; B: It shows plasma ethanol levels; C: It shows plasma acetate levels. Data are presented as mean ± SEM (n = 9). Statistical analysis was performed using one-way analysis of variance followed by Dunnett’s multiple comparison test. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs disease control group. ALT: Alanine aminotransferase; PO: Orally; OD: Once daily.